Utility of Assessing CD3(+) Cell Chimerism within the First Months after Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia.

International audienceAfter allogeneic hematopoietic stem-cell transplantation (alloHSCT), the chimerism assay is used to monitor cell engraftment and quantify the respective proportions of donor/recipient cells in blood or bone-marrow samples. Here, we aimed to better assess the utility of determining CD3(+) cell chimerism within the first 6\,months post alloHSCT. One hundred and thirty five patients diagnosed with acute myeloid leukemia were enrolled in this study. We observed significantly lower overall survival and relapse free survival for patients without full donor chimerism (<95%, <98%,